Merck & Co., Inc. (MRK) Projected to Post Quarterly Earnings on Thursday

Merck & Co., Inc. (NYSE:MRK) will likely be issuing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $2.37 per share and revenue of $17.0026 billion for the quarter. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS.Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 9:00 AM ET.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. On average, analysts expect Merck & Co., Inc. to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Down 0.0%

NYSE MRK opened at $87.60 on Thursday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $107.36. The company has a 50 day moving average of $84.28 and a 200-day moving average of $81.43. The company has a market cap of $218.81 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.96 and a beta of 0.37.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MRK. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price target for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company dropped their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Finally, Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $104.33.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Chapman Financial Group LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter worth $84,000. Semmax Financial Advisors Inc. grew its stake in shares of Merck & Co., Inc. by 32.9% during the second quarter. Semmax Financial Advisors Inc. now owns 1,596 shares of the company’s stock worth $129,000 after buying an additional 395 shares during the last quarter. WFA of San Diego LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter worth $195,000. Palisade Capital Management LP bought a new stake in shares of Merck & Co., Inc. during the second quarter worth $205,000. Finally, White Knight Strategic Wealth Advisors LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter worth $242,000. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.